The Efficacy and Safety of Dermocosmetic Cream Containing Bakuchiol and Salicylic Acid in the Treatment of Mild‐to‐Moderate Severity of Acne Vulgaris: A Noninferiority Randomized Controlled Trial
Dermatologic Therapy · 2026-01 · 2026 (1)
DOI: 10.1155/dth/6667172 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Dermatologic Therapy, online erschienen am 09.07.2026. Verfasst von Patcharapong Rujirawan und 3 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Bakuchiol has emerged in dermocosmetics for its antiacne effect. More data are needed regarding its efficacy in treating acne vulgaris (AV). The aim is to investigate efficacy and safety of dermocosmetic‐containing bakuchiol and salicylic acid (BSA) for AV.
Methods
In this 12‐week, noninferior trial, 70 participants with mild‐to‐moderate AV (investigator global assessment [IGA] Scores 1–3) were allocated randomly into two arms, BSA twice daily and 0.025% tretinoin cream once nightly. Dermatologists assessed participants at baseline and 4, 8, and 12 weeks on acne counts and IGA and performed skin hydration, transepidermal water loss (TEWL), and skin surface lipid (SSL) measurement using corneometer, tewameter, and sebumeter. Investigators recorded side effects throughout the study. Noninferiority margin was defined as 5‐lesion reduction difference between groups at Week 12.
Results
Sixty‐six (94%) participants completed the study. Primary objective was within noninferior margin (95%CI = −6.71, 2.49). Both arms demonstrated significant reductions in total acne count and IGA compared to baseline. Additionally, BSA revealed significant higher improvement in acne severity than tretinoin at Week 4 ( p = 0.023). Regarding skin parameters, tretinoin showed significantly reduced skin hydration at Week 12 ( p = 0.026), while BSA did not show statistical difference. TEWL increased significantly in the tretinoin group compared to BSA at the end of study ( p = 0.038). SSL in the BSA group significantly decreased at Weeks 8 and 12 compared to tretinoin ( p = 0.041, 0.008). Acne flare (BSA vs. tretinoin, 34.38% vs. 58.82%, p = 0.047) and dryness (8.13% vs. 52.94%, p = 0.040) were significantly lower throughout the study.
Conclusions
BSA’s efficacy was not inferior to tretinoin in treating mild‐to‐moderate AV. It also showed favorable side effects. Trial Registration: Clinical trial.gov.identifier: 20230809001
Zitieren
APA
Rujirawan, P., Chongpison, Y., Noppakun, N., & Kumtornrut, C. (2026). The Efficacy and Safety of Dermocosmetic Cream Containing Bakuchiol and Salicylic Acid in the Treatment of Mild‐to‐Moderate Severity of Acne Vulgaris: A Noninferiority Randomized Controlled Trial. Dermatologic Therapy, 2026(1). https://doi.org/10.1155/dth/6667172
Vancouver
Rujirawan P, Chongpison Y, Noppakun N, Kumtornrut C. The Efficacy and Safety of Dermocosmetic Cream Containing Bakuchiol and Salicylic Acid in the Treatment of Mild‐to‐Moderate Severity of Acne Vulgaris: A Noninferiority Randomized Controlled Trial. Dermatologic Therapy. 2026;2026(1). doi:10.1155/dth/6667172
BibTeX
@article{Rujirawan2026,
author = {Rujirawan, Patcharapong and Chongpison, Yuda and Noppakun, Nopadon and Kumtornrut, Chanat},
title = {The Efficacy and Safety of Dermocosmetic Cream Containing Bakuchiol and Salicylic Acid in the Treatment of Mild‐to‐Moderate Severity of Acne Vulgaris: A Noninferiority Randomized Controlled Trial},
journal = {Dermatologic Therapy},
year = {2026},
volume = {2026},
number = {1},
doi = {10.1155/dth/6667172}
}
EUVIMED